title: Misoprostol in labor induction.
abstract: The efficacy of a new dosing regimen of misoprostol, a recently introduced labor-inducing agent, was studied. Fifty-eight patients received 50 microg of misoprostol intravaginally and the dose was repeated every 3 hours until uterine contractions begin. Those who had an adequate contraction pattern, defined as three contractions in 10 minutes, were not given the repeat dose. Oxytocin augmentation, but not further misoprostol doses, was used in patients with an inadequate contraction pattern. The maximum total daily dose was 200 microg. The patients had the mean age of 28.9 +/- 5.4, the mean gestational age of 211.8 +/- 46.6 days, the mean gravidity of 2.5 +/- 1.2, the mean parity of 0.9 +/- 0.9 and the mean initial Bishop score of 1.6 +/- 1.8. The mean required dose of misoprostol was 120.5 +/- 54.7 microg and 10 of 58 patients required oxytocin augmentation. The mean induction of labor to delivery time was 701.5 +/- 404.0 minutes. When 3 cases who gave birth with caesarean section were excluded, the interval was 708.4 +/- 407.2 minutes. The mean 5th minute Apgar score of the newborns was 8.2 +/- 2.5. Two patients developed tachysystole after the second dose of misoprostol and were managed with vaginal irrigation and O2 supplementation successfully. Slight nausea and vomiting in 2 patients were the other adverse reactions. Our findings revealed that, 50 microg intravaginal misoprostol, combined with oxytocin augmentation when necessary, appears to be an effective and safe method of labor induction.
authors.affiliation: Department of Obstetrics and Gynaecology, Uludag University Medical Faculty, Bursa, Turkey.
authors.forename: H
authors.initials: H
authors.lastname: Ozan
authors.forename: G
authors.initials: G
authors.lastname: Uncu
authors.forename: V
authors.initials: V
authors.lastname: Yildirim
authors.forename: M
authors.initials: M
authors.lastname: Omak
authors.forename: H F
authors.initials: HF
authors.lastname: Kara
authors.forename: M
authors.initials: M
authors.lastname: Tüfekçi
mesh_terms: D000282:Administration, Intravaginal; D000328:Adult; D020070:Cervical Ripening; D005260:Female; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage*; D010120:Oxytocics / Q000008:administration & dosage*; D011247:Pregnancy; D011256:Pregnancy Outcome
chemical_list: D010120:Oxytocics; D016595:Misoprostol